Business Description

ARCA biopharma Inc
NAICS : 325413
SIC : 2835
Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 151.59 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 44.3 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 40.7 | |||||
3-Year Book Growth Rate | -15.4 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 44.29 | |||||
9-Day RSI | 42.2 | |||||
14-Day RSI | 42.5 | |||||
6-1 Month Momentum % | -1.88 | |||||
12-1 Month Momentum % | -12.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 37.72 | |||||
Quick Ratio | 37.72 | |||||
Cash Ratio | 37.5 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -108.3 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -21.73 | |||||
ROA % | -20.5 | |||||
ROIC % | -1277.24 | |||||
ROC (Joel Greenblatt) % | -2481.5 | |||||
ROCE % | -23.04 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.72 | |||||
Price-to-Tangible-Book | 0.72 | |||||
EV-to-EBIT | 1.15 | |||||
EV-to-EBITDA | 1.16 | |||||
EV-to-FCF | 1.12 | |||||
Price-to-Net-Current-Asset-Value | 0.72 | |||||
Price-to-Net-Cash | 0.73 | |||||
Earnings Yield (Greenblatt) % | 86.96 |
How ARCA biopharma Inc (ABIO) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABIO
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.69 | ||
Beta | 1.25 | ||
Volatility % | 25.96 | ||
14-Day RSI | 42.5 | ||
14-Day ATR ($) | 0.075628 | ||
20-Day SMA ($) | 2.145865 | ||
12-1 Month Momentum % | -12.18 | ||
52-Week Range ($) | 1.7645 - 2.6999 | ||
Shares Outstanding (Mil) | 14.41 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ARCA biopharma Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |
ARCA biopharma Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
ARCA biopharma Inc Frequently Asked Questions
What is ARCA biopharma Inc(ABIO)'s stock price today?
The current price of ABIO is $2.08. The 52 week high of ABIO is $2.70 and 52 week low is $1.76.
When is next earnings date of ARCA biopharma Inc(ABIO)?
The next earnings date of ARCA biopharma Inc(ABIO) is 2023-05-02 Est..
Does ARCA biopharma Inc(ABIO) pay dividends? If so, how much?
ARCA biopharma Inc(ABIO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |